Answers to common questions about AntibodyLLM's AI antibody engineering platform, services, and technology.
AntibodyLLM is an AI-powered antibody engineering and contract research/manufacturing platform founded in 2020 and commercially launched in 2024. Headquartered in Houston, TX, the platform combines large language model (LLM)-based antibody design with a proprietary deterministic CHO cell expression system to deliver faster, higher-yield antibody development.
AI improves antibody engineering by predicting sequence-structure-function relationships before wet-lab experiments. AntibodyLLM's platform uses large language models to design antibody sequences optimized for affinity, stability, and expressibility — enabling generative design of novel sequences and multi-objective optimization. This reduces failed experiments and compresses development timelines by up to 50% compared to traditional iterative approaches.
CRISPR site-specific integration inserts the gene of interest into a predetermined, transcriptionally active location in the host cell genome. Unlike random integration, this eliminates positional variability — the leading cause of clone-to-clone inconsistency in traditional cell line development. AntibodyLLM's CRISPR platform delivers consistent high expression levels without screening hundreds of clones.
UCOE (Ubiquitous Chromatin Opening Element) is a DNA element derived from human housekeeping gene promoters that maintains an open chromatin configuration around the integrated transgene. In stable CHO cell lines, UCOE prevents epigenetic silencing (methylation-mediated gene inactivation) that can occur during long-term culture — ensuring sustained high expression levels for 50+ generations.
AntibodyLLM's CRISPR + UCOE platform delivers stable, high-yield CHO cell lines in 10–12 weeks. In fast-track cases, delivery has been achieved in as little as 8 weeks — approximately 50% faster than the industry-standard 16–20 week timeline.
AntibodyLLM has demonstrated yields of 3.2 g/L (a 3× / 220% improvement over baseline 1.0 g/L) for IgG antibodies. Production scales from transient expression (μg–mg, 1–2 weeks) through large-scale bioreactors (10L–1000L).
AntibodyLLM can produce: monoclonal antibodies (mAbs), bispecific antibodies, antibody fragments (Fab, scFv, nanobodies), Fc-fusion proteins, enzymes, cytokines, growth factors, and recombinant antigens for diagnostic and therapeutic applications.
Yes. AntibodyLLM offers full bispecific antibody development including AI-guided construct design (knobs-into-holes, CrossMab, and other formats), chain pairing optimization, expression optimization, and purification strategy development. The AI platform specifically addresses the chain mispairing and reduced yield challenges common in bispecific production.
AntibodyLLM reports a 95%+ project success rate, compared to an industry average where 30–50% of traditional antibody projects fail or require significant re-work.
Yes. AntibodyLLM offers OEM and ODM contract manufacturing for both diagnostic and therapeutic antibody applications, from mg-scale research batches to kg-scale commercial production.
Submit your sequence, target description, or project requirements via our contact form. The team will review your project and provide a custom proposal and timeline.
Our scientific team is ready to discuss your project and provide expert guidance.
Contact Our Team